Read more http://www.eurekalert.org/pub_releases/2011-04/ifqa-lsf042711.php
Wednesday, 27 April 2011 14:30
Long struggle for appropriately processed manufacturer data leads to a new assessment of memantine
After the manufacturer of the Alzheimer's drug memantine submitted a supplementary analysis of study data, the German Institute for Quality and Efficiency in Health Care (IQWiG) sees proof of a benefit of the drug for cognitive function, as well as indications of a benefit for activities of daily living, at least for a treatment period of 6 months. This changes the conclusions of the first IQWiG benefit assessment of 2009.
Read 492 times
|
Published in
Psychology News
